Arcutis Biotherapeutics, Inc. (ARQT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 50M 100M 150M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 725K Q4 '22: 3M Q1 '23: 2.8M Q2 '23: 5.2M Q3 '23: 38.1M Q4 '23: 13.5M Q1 '24: 49.6M Q2 '24: 30.9M Q3 '24: 44.8M Q4 '24: 71.4M Q1 '25: 65.8M Q2 '25: 81.5M Q3 '25: 99.2M Q4 '25: 129.5M Q1 '26: 105.4M Q2 '26: 129.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 50M 100M 150M Q1 '23: 2M Q2 '23: 4.4M Q3 '23: 36.9M Q4 '23: 11.3M Q1 '24: 46.3M Q2 '24: 27.4M Q3 '24: 39.3M Q4 '24: 64.5M Q1 '25: 57M Q2 '25: 74M Q3 '25: 90.5M Q4 '25: 117.8M Q1 '26: 95.6M Q2 '26: 118.9M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q1 '19: -7M Q2 '19: -8.5M Q3 '19: -14.6M Q4 '19: -13M Q1 '20: -28.7M Q2 '20: -35.6M Q3 '20: -38.3M Q4 '20: -34.1M Q1 '21: -36.1M Q2 '21: -42.1M Q3 '21: -57.1M Q4 '21: -71.3M Q1 '22: -62.6M Q2 '22: -65.8M Q3 '22: -104.7M Q4 '22: -68.4M Q1 '23: -76.3M Q2 '23: -66.8M Q3 '23: -36.9M Q4 '23: -61.2M Q1 '24: -31.6M Q2 '24: -50.1M Q3 '24: -39.1M Q4 '24: -7.6M Q1 '25: -24.5M Q2 '25: -14.6M Q3 '25: 8.5M Q4 '25: 18.4M Q1 '26: -9.1M Q2 '26: 16.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q1 '19: -6.7M Q2 '19: -8.3M Q3 '19: -14.5M Q4 '19: -12.6M Q1 '20: -28M Q2 '20: -35.4M Q3 '20: -38.2M Q4 '20: -34M Q1 '21: -36M Q2 '21: -42M Q3 '21: -57M Q4 '21: -71.3M Q1 '22: -64.3M Q2 '22: -67.4M Q3 '22: -107.7M Q4 '22: -72M Q1 '23: -80.1M Q2 '23: -71M Q3 '23: -44.8M Q4 '23: -66.3M Q1 '24: -35.4M Q2 '24: -52.3M Q3 '24: -41.5M Q4 '24: -10.8M Q1 '25: -25.1M Q2 '25: -15.9M Q3 '25: 7.4M Q4 '25: 17.4M Q1 '26: -11.3M Q2 '26: 15M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

0 4M 8M 12M Q1 '23: 783K Q2 '23: 776K Q3 '23: 1.2M Q4 '23: 2.2M Q1 '24: 3.3M Q2 '24: 3.5M Q3 '24: 5.5M Q4 '24: 6.9M Q1 '25: 8.8M Q2 '25: 7.5M Q3 '25: 8.7M Q4 '25: 11.7M Q1 '26: 9.8M Q2 '26: 10.9M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '19: -7.1M Q2 '19: -8.2M Q3 '19: -10.7M Q4 '19: -16.8M Q1 '20: -21M Q2 '20: -25.8M Q3 '20: -33.7M Q4 '20: -32.6M Q1 '21: -46.2M Q2 '21: -35.8M Q3 '21: -40.9M Q4 '21: -51.7M Q1 '22: -57M Q2 '22: -62M Q3 '22: -67.7M Q4 '22: -71.1M Q1 '23: -80.3M Q2 '23: -66.5M Q3 '23: -44M Q4 '23: -56.2M Q1 '24: -31.6M Q2 '24: -45.1M Q3 '24: -34.7M Q4 '24: -748K Q1 '25: -30.4M Q2 '25: 324K Q3 '25: -1.8M Q1 '26: 2.2M Q2 '26: 12.6M Q1 '19 Q1 '20 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '19: -7.3M Q2 '19: -8.3M Q3 '19: -10.7M Q4 '19: -16.9M Q1 '20: -21.1M Q2 '20: -25.8M Q3 '20: -33.8M Q4 '20: -32.7M Q1 '21: -46.8M Q2 '21: -35.9M Q3 '21: -41M Q4 '21: -52M Q1 '22: -57.1M Q2 '22: -62.1M Q3 '22: -67.7M Q4 '22: -71.2M Q1 '23: -80.4M Q2 '23: -66.8M Q3 '23: -44M Q4 '23: -56.2M Q1 '24: -31.6M Q2 '24: -45.1M Q3 '24: -34.8M Q4 '24: -748K Q1 '25: -31M Q2 '25: 246K Q3 '25: -1.8M Q1 '26: 2.2M Q2 '26: 12.5M Q1 '19 Q1 '20 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 37.6M Q3 '20: 37.7M Q1 '21: 47.3M Q2 '21: 50M Q3 '21: 50.1M Q1 '22: 50.5M Q2 '22: 51.4M Q3 '22: 57.1M Q1 '23: 61.2M Q2 '23: 61.4M Q3 '23: 61.7M Q1 '24: 111M Q2 '24: 123.5M Q3 '24: 124.3M Q1 '25: 126K Q2 '25: 127M Q3 '25: 132.9M Q1 '26: 129.4K Q2 '26: 135.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '19: -22.46 Q1 '20: -19.53 Q2 '20: -15.78 Q3 '20: -9.23 Q4 '20: -3.84 Q1 '21: -3.45 Q2 '21: -3.35 Q3 '21: -3.48 Q4 '21: -4.17 Q1 '22: -4.68 Q2 '22: -5.15 Q3 '22: -5.90 Q4 '22: -5.61 Q1 '23: -5.65 Q2 '23: -5.50 Q3 '23: -4.34 Q4 '23: -3.79 Q1 '24: -2.80 Q2 '24: -2.06 Q3 '24: -1.66 Q4 '24: -1.15 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.